Synopsis
Recent advances in MRI for liver fat, iron, and fibrosis quantification has enabled “virtual liver biopsy” for patients with diffuse liver disease, and these technologies are now widely available for clinical care. The purpose of this educational session is to inform physicians and physicists of these new MRI capabilities and their potential value in clinical practice.
Target Audience
Physicians and scientists interested in liver MRI for diffuse liver disease characterization Objectives
Understand –
· Biophysical basis of liver fat, iron and fibrosis quantification by respective MRI biomarkers: proton-density fat fraction, R2*, and elastic modulus
· Pulse sequence design for biomarker quantification
· Existing validation data for diffuse liver disease MRI biomarkers
Practice –
· Interpret proton-density fat fraction, R2*, and elasticity maps of the liver and synthesize diagnosis
· Identify issues in acquisition, reconstruction, and other pitfalls, and take appropriate corrective actions
Purpose
Diffuse liver disease represents a spectrum of liver parenchymal pathology often associated with viral, alcoholic, metabolic (non-alcoholic), drug-induced, autoimmune etiologies. Diffuse liver disease has become exceedingly common worldwide, prompting the clinical need for objective noninvasive methods for disease characterization, as an alternative or complement to gold-standard liver biopsy. Recent advances in MRI for liver fat, iron, and fibrosis quantification has enabled “virtual liver biopsy”, and these technologies are now widely available for routine clinical care. The purpose of this educational session is to inform physicians and physicists of these new MRI capabilities and their potential value in their clinical practice.Acknowledgements
No acknowledgement found.References
No reference found.